Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

Gower Publishing

- PMLiVE

Kathy O’Connell joins Research Partnership as Senior Vice President, Business Development

Kathy has been working in the pharmaceutical market research industry for over 25 years. She has a diverse business background, with in-depth experience in progressively responsible sales, business development and...

Research Partnership

regeneron headquarters

Regeneron and Mammoth announce gene editing partnership worth $370m per target

The companies will aim to develop CRISPR-based therapies for multiple tissues and cell types

- PMLiVE

BeiGene’s Tizveni receives EC approval to treat non-small cell lung cancer

Under the brand name Tevimbra, the company will combine the NSCLC indications with the second-line ESCC indication in late 2024

Biogen Idec building

Biogen’s tocilizumab biosimilar Tofidence recommended by CHMP to treat arthritis and COVID-19

The committee’s decision was supported by evidence demonstrating Tofidence’s similarity to Roche’s RoActemra

- PMLiVE

Sanofi presents positive phase 3 results for rilzabrutinib in immune thrombocytopenia

The late-stage LUNA 3 study results will be presented at a medical congress later this year

- PMLiVE

The princess, the queen and the grandfather

Three important voices, many important lessons

Enhancing Focus in Virtual Meetings: Stick to a Theme – Impetus InSite Tips #5

Focus your virtual meetings with a clear theme! Tip 5 from our ImpetusInSite Tips series shows how sticking to one theme per touchpoint can dramatically improve engagement and coherence. Learn...

Impetus Digital

- PMLiVE

J&J and Legend’s Carvykti receives EC approval to treat relapsed and refractory multiple myeloma

The BCMA-targeted therapy is the first to receive approval in Europe for RRMM patients as early as first relapse

- PMLiVE

Astellas announces EC approval of Xtandi for expanded prostate cancer use

Up to 40% of patients who have undergone definitive prostate cancer treatment will experience biochemical recurrence within ten years

- PMLiVE

AI drug discovery biotech Xaira Therapeutics launches with over $1bn in committed funding

The company combines machine learning, data generation and therapeutic product development

- PMLiVE

Novartis’ Lutathera receives FDA approval to treat neuroendocrine tumours in paediatric patients

The incidence of neuroendocrine tumours has increased over the past several decades

- PMLiVE

FDA grants Day One’s Ojemda accelerated approval for paediatric low-grade glioma

The type 2 RAF inhibitor is the first and only one approved in the US to treat this patient population

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links